Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)”In the company’s words, NCT04278131 on ClinicalTrials.gov
- Tested for
- Retinitis Pigmentosa, Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
- Main trialPhase 1/2
- “A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa”In the company’s words, NCT04278131 on ClinicalTrials.gov
Other drugs for Retinitis Pigmentosa
- RTx-015Ray Therapeutics, Inc. · Phase 2/3
- N-acetylcysteine amideNacuity Pharmaceuticals, Inc. · Phase 3
- Voretigene neparvovec-rzylSpark Therapeutics, Inc. · Phase 3
- FamzeretceljCyte, Inc · Phase 2
- SPVN06SparingVision · Phase 1/2
- OCU400Ocugen · Phase 1/2
Coming up2
- 30 DecPhase 1/2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 30 Dec 2026 | BS01 in Patients With Retinitis Pigmentosa | |
| Phase 1/2Recruiting | Dec 2027 | A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026